Gilead Sciences's Remdesivir may cut Covid-19 risk of death by 62% | Sharecast.com

in hive-116221 •  4 years ago 

STEEM POSTS

Third phase clinical trial data presented by the company at the 23rd International AIDS conference showed that the treatment was associated with a 62% reduction in the risk of mortality and an improvement in clinical recovery.

However, the biotechnology company said the finding needed to be confirmed through prospective clinical trials.


Shared On DLIKE

Authors get paid when people like you upvote their post.
If you enjoyed what you read here, create your account today and start earning FREE STEEM!
Sort Order:  

Copying/Pasting full or partial texts without adding anything original is frowned upon by the community. Repeated copy/paste posts could be considered spam. Spam is discouraged by the community and may result in the account being Blacklisted.